Which pediatric patients should be screened for Wilson disease and what are the recommended first‑line screening tests?

Wilson's Disease Screening in Pediatrics

Which Pediatric Patients Require Screening

All first-degree relatives (siblings, children, and parents) of any newly diagnosed Wilson's disease patient must be screened, regardless of symptoms. 1, 2, 3 This is the single most important screening indication, as presymptomatic treatment prevents disease manifestations entirely and ensures near-normal longevity. 3, 4

Beyond family screening, specific clinical presentations in pediatric patients mandate investigation for Wilson's disease:

Hepatic Presentations Requiring Screening

• Any child presenting with clinical features of autoimmune hepatitis must be investigated for Wilson's disease 1, 2 - this is a Class I, Level B recommendation because these conditions are clinically and histologically indistinguishable in younger patients 1, 2
• Children with unexplained elevation of aminotransferases or hepatomegaly 3
• Pediatric patients with clinical picture resembling acute viral hepatitis 3
• Children presenting with nonalcoholic fatty liver disease or steatohepatitis findings 2

Fulminant Hepatic Failure Pattern

• Any pediatric patient with fulminant hepatic failure plus Coombs-negative hemolytic anemia, modest aminotransferase elevations (typically <2000 IU/L), and low alkaline phosphatase (typically <40 IU/L) with alkaline phosphatase-to-bilirubin ratio <2 1, 2 - this constellation is highly characteristic of Wilson's disease

Other Clinical Presentations

• Unexplained Coombs-negative hemolytic anemia 3
• Neuropsychiatric symptoms including tremor, dysarthria, dystonia, or "juvenile Parkinsonism" 3
• Recurrent hepatic disease with unexplained neurological symptoms 5

Age Considerations

• Wilson's disease should be suspected in any individual between ages 3 and 55 years with liver abnormalities of uncertain cause 3
• Very young children can have clinically evident liver disease from Wilson's disease 4
• Age alone should never exclude the diagnosis 3

Recommended First-Line Screening Tests

For Family Screening (First-Degree Relatives)

If molecular testing (ATP7B mutations or haplotype analysis) is available from the index patient, this is the most efficient primary screening strategy. 2, 3 This approach is now considered standard for testing asymptomatic siblings. 6, 7

When genetic testing is unavailable or as complementary testing, the comprehensive biochemical panel includes:

• Serum ceruloplasmin 1, 2, 3
• 24-hour urinary copper excretion (basal, without penicillamine) 1, 2, 3 - urine must be collected in copper-free containers 8
• Liver function tests including aminotransferases, albumin, conjugated and unconjugated bilirubin, and INR 1, 2, 3
• Complete blood count 1, 2
• Serum copper 1, 2
• Slit-lamp examination for Kayser-Fleischer rings 1, 2, 3

For Symptomatic Patients

The same comprehensive panel applies, with additional considerations:

• Liver biopsy with quantitative hepatic copper measurement should be performed in individuals without Kayser-Fleischer rings who have subnormal ceruloplasmin and abnormal liver tests 1, 2, 3
• Hepatic copper concentration >250 μg/g dry weight is diagnostic 5

Penicillamine Challenge Test

• This test is only standardized and validated in pediatric patients under 18 years 8
• Primary indication: when basal 24-hour urinary copper is <100 μg/24 hours (<1.6 μmol/24 hours) in symptomatic children where Wilson's disease is still suspected 8
• Protocol: 500 mg D-penicillamine orally at hour 0 and hour 12 of 24-hour urine collection 8
• Diagnostic threshold: >1600 μg/24 hours (>25 μmol/24 hours) with 100% predictive value in symptomatic patients 8
• Specificity: 93-98% compared to other liver diseases 8

Important Caveats

• Children with autoimmune hepatitis can have elevated post-challenge urinary copper, though typically not reaching the 25 μmol/24 hour threshold 8
• Recent data suggest lowering the basal urinary copper threshold to 0.64 μmol/24 hours may eliminate need for challenge testing 8
• If initial family screening is normal, repeat screening in 2-5 years should be considered 2
• Treatment should be initiated for all individuals over 3-4 years old identified as patients by family screening 1, 2

Newborn Screening Status

• Measurement of ceruloplasmin in dried-blood spots may promote detection, but further refinement is required before wide-scale implementation 2

The critical principle is that early diagnosis when asymptomatic results in near-normal longevity with good health, making aggressive family screening and maintaining high clinical suspicion in at-risk presentations essential. 4, 3